title: Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.
abstract: Sunitinib treatment benefits patients with metastatic renal cell carcinoma (mRCC), but response duration can vary widely and resistance is not predicted by standard measures. [¹⁸F]fluoro-2-deoxy-2-D-glucose positron emission tomography (FDG-PET) uptake is variable in mRCC, but changes in FDG-PET uptake may be useful in monitoring disease progression. Further work is needed to personalize treatment for patients with mRCC.
authors.affiliation: Divisions of Medical Oncology, Department of Medicine, and Urology, Duke University Medical Center, Durham, North Carolina, USA.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Harrison
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: George
mesh_terms: D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging* / Q000473:pathology*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology*; D009362:Neoplasm Metastasis; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18